via National Cancer Institute
- Test proved able to detect and indicate site of dozens of types of cancer with high accuracy according to recent study
- Dana-Farber joins multi-center trial to provide test results to patients for the first time
In a study involving thousands of participants, a new blood test detected more than 50 types of cancer as well as their location within the body with a high degree of accuracy, according to an international team of researchers led by Dana-Farber Cancer Institute and the Mayo Clinic.
The results, published online today by the Annals of Oncology, indicate that the test – which identified some particularly dangerous cancers that lack standard approaches to screening – can play a key role in early detection of cancer. Early detection can often be critical to successful treatment.
Developed by GRAIL, Inc., of Menlo Park, Calif., the test uses next-generation sequencing to analyze the arrangement of chemical units called methyl groups on the DNA of cancer cells. Adhering to specific sections of DNA, methyl groups help control whether genes are active or inactive. In cancer cells, the placement of methyl groups, or methylation pattern, is often markedly different from that of normal cells – to the extent that abnormal methylation patterns are even more characteristic of cancer cells than genetic mutations are. When tumor cells die, their DNA, with methyl groups firmly attached, empties into the blood, where it can be analyzed by the new test.
“Our previous work indicated that methylation-based tests outperform traditional DNA-sequencing approaches to detecting multiple forms of cancer in blood samples,” said Dana-Farber’s Geoffrey Oxnard, MD, co-lead author of the study with Minetta Liu, MD, of the Mayo Clinic. “The results of this study suggest that such assays could be a feasible way of screening people for a wide variety of cancers.”
In the study, investigators used the test to analyze cell-free DNA (DNA from normal and cancerous cells that had entered the bloodstream upon the cells’ death) in 6,689 blood samples, including 2,482 from people diagnosed with cancer and 4,207 from people without cancer. The samples from patients with cancer represented more than 50 cancer types, including breast, colorectal, esophageal, gallbladder, bladder, gastric, ovarian, head and neck, lung, lymphoid leukemia, multiple myeloma, and pancreatic cancer.
The overall specificity of the test was 99.3%, meaning that only 0.7% of the results incorrectly indicated that cancer was present. The sensitivity of the assay for 12 cancers that account for nearly two-thirds of U.S. cancer deaths was 67.3%, meaning the test could find the cancer two-thirds of the time but a third of the time the test returned a negative result. Within this group, the sensitivity was 39% for patients with stage I cancer, 69% for those with stage II, 83% for those with stage III, and 92% for those with stage IV. The stage I-III sensitivity across all 50 cancer types was 43.9%. When cancer was detected, the test correctly identified the organ or tissue where the cancer originated in more than 90% of cases – critical information for determining how the disease is diagnosed and managed.
“Our results show that this approach to testing cell-free DNA in blood can detect a broad range of cancer types at virtually any stage of the disease, with specificity and sensitivity approaching the level needed for population-level screening,” Oxnard observed. “The test can be an important part of clinical trials for early cancer detection.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Cancer test
- Only 28-years-old, Weymouth woman already beat ovarian cancer once
About 20,000 American women are diagnosed with the disease every year — that’s compared with more than 300,000 breast cancer diagnoses. The survival rates are similarly lopsided. After five years, 93 ...
- FDA greenlights Geneoscopy’s Colosense colorectal cancer screening test
This time a positive result for a cancer screening test brought good news, as Geneoscopy Inc. secured U.S. FDA approval for its RNA screening test for colorectal cancer. The agency based its decision ...
- Early onset bowel cancer cases increasing in New Zealand
There's a fresh call for a lowering of the bowel cancer screening age in Aotearoa New Zealand, in the wake of new University of Otago, Christchurch research showing an alarming rise in colorectal ...
- Everything to know about the new breast cancer screening guidelines for women 40+
New recommendations from the US Preventive Services Task Force suggest that women 40 and older now should receive a mammogram every other year until the age of 74. Biennial mammograms had previously ...
- Lung cancer is the deadliest of all cancers, and screening could save many lives—if more people could access it
Many medical organizations have been recommending lung cancer screening for decades for those at high risk of developing the disease.
Go deeper with Google Headlines on:
Cancer test
[google_news title=”” keyword=”cancer test” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Cancer blood test
- NEWS CENTER Maine anchor Lee Goldberg marks milestone in prostate cancer journey with PSA about PSAs
NEWS CENTER Maine's Morning Report anchor Lee Goldberg is reminding everyone with a prostate to get regular PSA tests.
- Geneoscopy wins FDA approval for Labcorp-partnered colon cancer test
Colosense analyzes stool samples for blood and RNA markers associated with abnormal colorectal tissue. In a clinical trial, the test achieved 93% sensitivity for colorectal cancer in average-risked ...
- Lawmaker seeks elimination of multi-cancer screening test for firefighters in Senate bill
Firefighters say an increased risk of cancer is one of the dangers they face as they put their lives on the line every day.
- Scientists Reveal Cancer's Atomic Secrets—'Whole New Layer to Medicine'
By studying these ratios in yeast and mouse liver cells, the team found that cells that were growing extremely fast, similar to cancer cells, contained a noticeably higher ratio of hydrogen to ...
- Fighting Cancer: A Basic Guide To Checkpoint Inhibitors
People with cancer may encounter checkpoint inhibitors as a treatment option but may not know where to start. This article can help you learn more.
Go deeper with Google Headlines on:
Cancer blood test
[google_news title=”” keyword=”cancer blood test” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]